DMK Pharmaceuticals Gross Profit

DMK Pharmaceuticals (DMK) currently reports a gross profit of $-1.4M as of December 2022. That compares with $-4.7M in the prior-year period — up 69.3% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore DMK Pharmaceuticals's gross profit history and peer comparisons.

DMK Pharmaceuticals's gross profit increased from $-4.7M to $-1.4M — a 69.3% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

DMK Pharmaceuticals's gross profit of $-1.4M is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

DMK Pharmaceuticals reported $-1.4M in gross profit as of December 2022. That compares with $-4.7M in the prior-year period — up 69.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-1.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for DMK Pharmaceuticals, and consider following DMK for alerts when major investors trade the stock.